Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,759 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results.
Lindeman GJ, Fernando TM, Bowen R, Jerzak KJ, Song X, Decker T, Boyle F, McCune S, Armstrong A, Shannon C, Bertelli G, Chang CW, Desai R, Gupta K, Wilson TR, Flechais A, Bardia A. Lindeman GJ, et al. Among authors: chang cw. Clin Cancer Res. 2022 Aug 2;28(15):3256-3267. doi: 10.1158/1078-0432.CCR-21-3811. Clin Cancer Res. 2022. PMID: 35583555 Free PMC article. Clinical Trial.
Low-pass Whole-genome Sequencing of Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort.
Chen X, Chang CW, Spoerke JM, Yoh KE, Kapoor V, Baudo C, Aimi J, Yu M, Liang-Chu MMY, Suttmann R, Huw LY, Gendreau S, Cummings C, Lackner MR. Chen X, et al. Among authors: chang cw. Clin Cancer Res. 2019 Apr 1;25(7):2254-2263. doi: 10.1158/1078-0432.CCR-18-1593. Epub 2019 Jan 7. Clin Cancer Res. 2019. PMID: 30617129
Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts.
Hutchinson KE, Yost SE, Chang CW, Johnson RM, Carr AR, McAdam PR, Halligan DL, Chang CC, Schmolze D, Liang J, Yuan Y. Hutchinson KE, et al. Among authors: chang cw, chang cc. Clin Cancer Res. 2020 Feb 1;26(3):657-668. doi: 10.1158/1078-0432.CCR-19-1773. Epub 2019 Oct 14. Clin Cancer Res. 2020. PMID: 31611282 Free PMC article.
A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors.
Tolaney SM, Do KT, Eder JP, LoRusso PM, Weekes CD, Chandarlapaty S, Chang CW, Chen SC, Nazzal D, Schuth E, Brunstein F, Carrasco-Triguero M, Darbonne WC, Giltnane JM, Flanagan WM, Commerford SR, Ungewickell A, Shapiro GI, Modi S. Tolaney SM, et al. Among authors: chang cw. Clin Cancer Res. 2020 Nov 1;26(21):5588-5597. doi: 10.1158/1078-0432.CCR-20-1067. Epub 2020 Jul 21. Clin Cancer Res. 2020. PMID: 32694157 Free PMC article. Clinical Trial.
Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinib.
Dziadziuszko R, Hung T, Wang K, Choeurng V, Drilon A, Doebele RC, Barlesi F, Wu C, Dennis L, Skoletsky J, Woodhouse R, Li M, Chang CW, Simmons B, Riehl T, Wilson TR. Dziadziuszko R, et al. Among authors: chang cw. Mol Oncol. 2022 May;16(10):2000-2014. doi: 10.1002/1878-0261.13214. Epub 2022 Apr 22. Mol Oncol. 2022. PMID: 35338679 Free PMC article.
The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 -) advanced/metastatic breast cancer.
Bardia A, Mayer I, Winer E, Linden HM, Ma CX, Parker BA, Bellet M, Arteaga CL, Cheeti S, Gates M, Chang CW, Fredrickson J, Spoerke JM, Moore HM, Giltnane J, Friedman LS, Chow Maneval E, Chan I, Jhaveri K. Bardia A, et al. Among authors: chang cw. Breast Cancer Res Treat. 2023 Jan;197(2):319-331. doi: 10.1007/s10549-022-06797-9. Epub 2022 Nov 19. Breast Cancer Res Treat. 2023. PMID: 36401732 Free PMC article.
Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial.
Landen CN, Molinero L, Hamidi H, Sehouli J, Miller A, Moore KN, Taskiran C, Bookman M, Lindemann K, Anderson C, Berger R, Myers T, Beiner M, Reid T, Van Nieuwenhuysen E, Green A, Okamoto A, Aghajanian C, Thaker PH, Blank SV, Khor VK, Chang CW, Lin YG, Pignata S. Landen CN, et al. Among authors: chang cw. Clin Cancer Res. 2023 May 1;29(9):1698-1707. doi: 10.1158/1078-0432.CCR-22-2032. Clin Cancer Res. 2023. PMID: 36595569 Free PMC article.
An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer.
Chandarlapaty S, Dickler MN, Perez Fidalgo JA, Villanueva-Vázquez R, Giltnane J, Gates M, Chang CW, Cheeti S, Fredrickson J, Wang X, Collier A, Moore HM, Metcalfe C, Lauchle J, Humke EW, Bardia A. Chandarlapaty S, et al. Among authors: chang cw. Clin Cancer Res. 2023 Aug 1;29(15):2781-2790. doi: 10.1158/1078-0432.CCR-23-0011. Clin Cancer Res. 2023. PMID: 37261814 Free PMC article. Clinical Trial.
1,759 results